07:51 AM EDT, 06/13/2025 (MT Newswires) -- GSK (GSK) said Friday that the European Medicines Agency accepted its application to expand the use of its adjuvanted recombinant respiratory syncytial virus vaccine, Arexvy, to adults aged 18 and older.

The company said Arexvy is currently approved in Europe for adults above 60 and for those 50-59 at higher risk of RSV-related lower respiratory tract disease.

A regulatory decision is expected in H1 2026, the company said, adding it is also pursuing expanded approvals in the US, Japan, and other regions.